https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-om-staging.hbrsd.com/media/dydjvcpi/adobestock_526526544.jpg
Ophthalmology Management
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-om-staging.hbrsd.com/media/a1lfxny5/rp1026_aao_digital_cover_v1.jpg
Retinal Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-om-staging.hbrsd.com/media/0eypbm5l/0926_fc_gp.jpg
Glaucoma Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-om-staging.hbrsd.com/media/0jsmmz3o/op_1025_cover_final.jpg
Ophthalmic Professional
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-om-staging.hbrsd.com/media/tmzkk4zx/1026_oasc_cover_large.jpg
The Ophthalmic ASC
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-om-staging.hbrsd.com/media/aqbjxwjw/pp-cover.jpg
Presbyopia Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-om-staging.hbrsd.com/media/npjdtl1w/cp_november_cover.jpg
Corneal Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-om-staging.hbrsd.com/media/mvqdq2hc/nrp_cover_october_2024.jpg
New Retinal Physician
Wednesday, October 28, 2026
The FDA questioned whether results from the pivotal SYD-101-001 trial of Sydnexis' investigational atropine sulfate ophthalmic solution 0.01% demonstrate a clinically meaningful benefit.
Wednesday, October 28, 2026
Approval was supported by a phase 3 study involving 582 patients with wet AMD; a US launch is planned for 2027.
Tuesday, October 27, 2026
Phase 2 data showed tumor shrinkage in approximately 80% of patients, with 57% of those initially recommended for enucleation preserving their eyes.
Thursday, October 22, 2026
Privosegtor reduced post-onset increases in plasma neurofilament light chain and glial fibrillary acidic protein compared with placebo
Wednesday, October 21, 2026
Brepocitinib 45 mg once-daily achieved statistically significant benefit compared to placebo on the primary and all key secondary endpoints for each of CLARITY-1 and CLARITY-2
Wednesday, October 21, 2026
The $550 million acquisition brings Alcon an FDA-approved treatment for patients with MacTel type 2.
Monday, October 19, 2026
The genotype-guided trial enrolled 176 patients to evaluate licaminlimab for dry eye disease, with topline results expected around year-end 2026.
Monday, October 19, 2026
The trial results showed a 37% reduction in mean IOP, with 86% of patients remaining off topical IOP-lowering medications at 4 years.
Monday, October 19, 2026
Following the failure of its second pivotal Duravyu trial to demonstrate noninferiority to aflibercept, EyePoint plans to cut its workforce by 53% and terminate its nAMD trials early.
Monday, October 19, 2026
The FDA identified counterfeit over-the-counter eye drops in Florida and Georgia, with bacterial contamination confirmed in 2 products.
Monday, October 19, 2026
The expanded indication is supported by positive results from the pivotal phase 3 VEGA-2 and VEGA-3 clinical trials.
Friday, October 16, 2026
Brytly is approved for adults and children ages 12 years and older and should not be used more than twice daily.
Friday, October 16, 2026
New educational resources on inflammatory eye diseases, including uveitis, keratitis, conjunctivitis, and thyroid eye disease are being highlighted from October 19 to 25, 2026.
Friday, October 16, 2026
Genentech’s IL-6 receptor inhibitor becomes the first subcutaneous treatment approved for TED, with at-home administration every 4 weeks during maintenance.
Friday, October 16, 2026
The BETTIS‑1 trial met its primary endpoint, demonstrating a favorable safety profile across both EC-104 formulations compared to Ozurdex.
Thursday, October 15, 2026
Ask EyeDock AI is a clinical assistant for optometrists, ophthalmologists, opticians, and students.
Wednesday, October 14, 2026
The agreement gives Visara exclusive rights to develop and commercialize VIS-102 worldwide, excluding Greater China.
Tuesday, October 13, 2026
According to the company, 41% of CSB-001-treated eyes gained ≥15 letters compared to 0% in the no-treatment arm.
Monday, October 12, 2026
The trial met both co-primary endpoints with statistical significance in the intent-to-treat population at 6 months.
Friday, October 9, 2026
The study will evaluate how ST-100 supports epithelial and stromal healing in corneal wounds.
Friday, October 9, 2026
The deal will add IOL simulation for cataract surgery to the Carrot Platform and expand Carrot from vision diagnostics into vision simulation.
Friday, October 9, 2026
The study met its primary efficacy endpoint, demonstrating statistically significant superiority and clinically meaningful IOP reduction vs cataract surgery alone, according to the company.
Thursday, October 8, 2026
The recipients were recognized for their discoveries concerning light-gated ion channels and optogenetics.
Thursday, October 8, 2026
Six-month data on a new bioreinforced canaloplasty procedure show 37% IOP reduction, with new findings on bioreinforced cyclodialysis to be presented at AAO 2026.
Thursday, October 8, 2026
PIONEER trial findings show improvements in light sensitivity and measures of visual function in some patients with late-stage retinitis pigmentosa.
Thursday, October 8, 2026
The license agreement also grants Glaukos exclusive rights to the RevMod platform for the discovery and development of up to 4 additional next-generation biologics for various retinal diseases, the company said.
Thursday, October 8, 2026
Three-year data demonstrate sustained improvements in corneal shape, meaningful visual acuity gains, and a favorable long-term safety profile following a single treatment.
Wednesday, October 7, 2026
A post hoc analysis showed reduced growth rates across several optical coherence tomography biomarkers after treatment.
Wednesday, October 7, 2026
The new lens is designed for retinal examination and laser indirect ophthalmoscopy.
Tuesday, October 6, 2026
Launched from Topcon Healthcare, Oku combines AI, retinal imaging, and connected clinical data to identify disease risk earlier.
Tuesday, October 6, 2026
Harrow acquired worldwide rights to the dry eye treatment, excluding Japan.
Friday, October 2, 2026
Outlook Therapeutics has applied to the CMS for a permanent, product-specific HCPCS Level II J-code for Lytenava, as the company prepares to launch the wet AMD treatment in the United States.
Friday, October 2, 2026
The next-generation, implant-free MIGS technology enables single-pass canaloplasty followed by trabeculotomy and adds enhanced catheter visualization and automated viscodilation.
Friday, October 2, 2026
The acquisition gives SpyGlass manufacturing capacity for the IOL used in its investigational BIM-IOL System.
Friday, October 2, 2026
The partnership integrates Rayner’s eyejourney platform with Promptly’s Patient Experience Suite to automate patient enrollment and education for US eye care clinics
Thursday, October 1, 2026
Baseline data from the phase 2 eDREAM trial presented support patient-tailored microperimetry as a potential functional measure for geographic atrophy clinical trials, according to Galimedix Therapeutics.
Thursday, October 1, 2026
The agency established a capped-rental payment structure for the glaucoma device and separate payment for its goggles.
Thursday, October 1, 2026
At 18 months, foveal schisis closure was maintained in 7 of 9 treated eyes and was not observed in untreated eyes.
Thursday, October 1, 2026
At 12 months, treatment-naïve eyes with nAMD gained a mean 4.6 ETDRS letters, while previously treated eyes had a mean change of -0.1 letters.
Wednesday, September 30, 2026
4D Molecular Therapeutics has enrolled the first patients in 4SIGHT, a global phase 3 trial evaluating 4D-150, its investigational intravitreal gene therapy, in patients with diabetic macular edema.
Tuesday, September 29, 2026
Retrospective data from 63 eyes showed improvements in visual acuity, corneal curvature, and manifest spherical equivalent at 1 month.
Tuesday, September 29, 2026
The company plans to appeal the FDA’s March 2026 decision not to approve reproxalap for dry eye disease.
Tuesday, September 29, 2026
The proposed legislation would broaden screening coverage for people at increased risk and provide funding for community-based programs and glaucoma research.
Monday, September 28, 2026
Both investigational therapies met the primary endpoint for noninferiority to aflibercept in vision gains at 1 year.
Monday, September 28, 2026
FDA approval brings Rayner’s nondiffractive spiral IOL platform to the US market.
Friday, September 25, 2026
The October 30 meeting will review the NDA for the low-dose atropine formulation.
Friday, September 25, 2026
Practices have approximately 60 days to challenge potential scoring errors that could affect 2027 Medicare Part B payments.
Thursday, September 24, 2026
The trispecific antibody demonstrated noninferiority to active control ranibizumab for mean change from baseline in best-corrected visual acuity at week 52.
Thursday, September 24, 2026
The Class II recall addresses a stability issue that could cause the imaging system’s stand to tip over during movement.
Wednesday, September 23, 2026
AURN001 is a single-administration investigational regenerative cell therapy for corneal edema secondary to corneal endothelial dysfunction.
Wednesday, September 23, 2026
The FDA-approved indocyanine green injection is now commercially available for ophthalmic angiography and other medical procedures.
Tuesday, September 22, 2026
The ORBIT trial is evaluating the efficacy and safety of linsitinib in adults with moderate to severe active thyroid eye disease.
Monday, September 21, 2026
According to the study, 57.1% of patients educated with InSightVR selected an ATIOL, compared with 28.4% of patients who received standard education.
Monday, September 21, 2026
VISTA met its primary endpoint, demonstrating statistically significant low luminance visual acuity responder rates at Month 12 compared to the untreated control group.
Wednesday, September 16, 2026
Botond Roska, MD, and José-Alain Sahel, MD, have been awarded the 2026 António Champalimaud Vision Award.
Wednesday, September 16, 2026
The program brings sponsors and research institutions together earlier in the IND development process.
Tuesday, September 15, 2026
The FDA has assigned a Prescription Drug User Fee Act target action date of April 30, 2027.
Wednesday, September 9, 2026
MCO-010 could become the first gene-agnostic therapy approved to improve vision in patients with RP and severe vision loss.
Tuesday, September 8, 2026
An agreement with Virotek gives Kala exclusive US distribution rights for an ophthalmology genomic testing program.
Tuesday, September 8, 2026
The acquisition adds gildeuretinol (ALK-001), a phase 3 oral investigational medicine designed to target the underlying biology of Stargardt disease
Tuesday, September 8, 2026
The new Mix and Match feature allows surgeons to simulate different IOL combinations between each eye, helping patients experience personalized vision strategies before cataract surgery
Tuesday, September 8, 2026
PretestPro runs 4 eye exams in a single workflow on the Heru Prime wearable platform.
Thursday, September 3, 2026
Unity M has received CE Mark and regulatory approvals in India, Europe, Canada, Japan, and the United States, with inventory beginning to ship in September.
Thursday, September 3, 2026
Results demonstrate enVista Aspire and enVista Aspire toric deliver good distance and functional intermediate vision in a majority of patients, according to the study by Bausch + Lomb
Tuesday, September 1, 2026
Only 14% of perimenopausal, menopausal, and postmenopausal women recognize dry eye as a menopause-related symptom, according to a new survey from Bausch + Lomb.
Tuesday, September 1, 2026
The pivotal study is designed to support a biologics license application for Ocugen’s geographic atrophy gene therapy.
Tuesday, September 1, 2026
Two-year SALWEEN results demonstrated sustained vision and retinal improvements, with most patients extending treatment to 20-week intervals.
Thursday, August 27, 2026
To help educate the public on the importance of wearing proper eye protection while playing sports, Prevent Blindness offers free sports eye safety information including a dedicated webpage, fact sheets, and shareable social media graphics.
Thursday, August 27, 2026
The system is expected to become available in selected European countries from September 2026, with wider global availability to follow.
Wednesday, August 26, 2026
The new platform features streamlined workflows and enhanced patient-at-a-glance functionality.
Tuesday, August 25, 2026
TRPV1 antagonist met the primary endpoint in a capsaicin-induced pain model, with phase 2 results expected in the coming months.
Tuesday, August 25, 2026
Phase 2 results support advancement to phase 3 with a primary endpoint at day 15.
Monday, August 24, 2026
The over-the-counter eye drop was voluntarily recalled nationwide due to a lack of assurance of sterility and potential contamination.
Monday, August 24, 2026
The primary endpoint is the proportion of patients achieving a gain of at least 15 letters from baseline at month 3.
Monday, August 24, 2026
Kodiak Sciences has enrolled the first patients in ALTO, a global phase 3 trial evaluating KSI-501, an investigational bispecific therapy targeting vascular endothelial growth factor and interleukin 6, in patients with diabetic macular edema.
Friday, August 21, 2026
Patients reported approximately 58% less discomfort overall in the Iheezo-treated eye, with the largest absolute differences in the immediate postinjection period, when discomfort is highest, according to Harrow.
Thursday, August 20, 2026
Expanded label makes TearCare the first and only MGD treatment indicated to improve meibomian gland function in adults with evaporative dry eye disease, according to Sight Sciences.
Wednesday, August 19, 2026
Zeiss Clinic 360 is part of the Zeiss ophthalmic workflow portfolio and will be available in the United States in early Fall 2026.
Tuesday, August 18, 2026
CMS established reimbursement for the Fsyx pump and goggles ahead of a planned fourth-quarter commercial launch.
Tuesday, August 18, 2026
Findings demonstrate corneal epithelial resolution in all eyes with complete follow-up, supporting decellularized basement membrane as an earlier intervention option for neurotrophic keratitis patients.
Tuesday, August 18, 2026
The study missed its primary endpoint in the full dataset but met several secondary endpoints.
Friday, August 14, 2026
According to Annexon Biosciences, the addition of a Month 24 dual primary endpoint will complement the current Month 15 primary endpoint in its phase 3 ARCHER II trial.
Thursday, August 13, 2026
The acquisition includes Nordic Pharma’s portfolio in ophthalmology.
Thursday, August 13, 2026
The study will assess 2 dose levels of the induced pluripotent stem cell–derived therapy in adults with retinitis pigmentosa.
Tuesday, August 11, 2026
An expert panel proposes a clinical decision framework after identifying differences in preoperative assessment, astigmatism management, and confidence with advanced-technology lens implantation.
Tuesday, August 11, 2026
Collaboration will enable ophthalmologists and optometrists to pair wavefront-guided diagnostics with scleral lens options.
Monday, August 10, 2026
Privosegtor (OCS-05) is an investigational neuroprotective candidate being developed for optic neuropathies and other neuro-axonal diseases.
Friday, August 7, 2026
Gildeuretinol (ALK-001) is an investigational once-daily oral therapy currently being evaluated in a phase 3 trial for Stargardt disease.
Friday, August 7, 2026
Most patients with advanced retinal disease experienced immediate improvements in near visual acuity after fitting with the wearable device.
Thursday, August 6, 2026
The acquisition expands the company's dry eye portfolio.
Wednesday, August 5, 2026
The system is the first FDA-cleared MIGS device for single pass canaloplasty with TruSync Plus, according to the company.
Tuesday, August 4, 2026
OPGx-LCA5 is the company’s investigational gene therapy for LCA5-associated inherited retinal disease.
Tuesday, August 4, 2026
Yesafili, a vascular endothelial growth factor (VEGF) inhibitor used to treat various types of ophthalmology conditions, is a biosimilar of its reference product Eylea (aflibercept 2 mg; Regeneron).
Tuesday, August 4, 2026
The over-the-counter Rohto Cooling Eye Drops were voluntarily recalled nationwide due to a lack of assurance of sterility.
Friday, July 31, 2026
According to the company, more than 480 patients with diabetic macular edema have been enrolled in the phase 3 trials evaluating Duravyu.
Thursday, July 30, 2026
Feasibility randomized trial found signals of improved visual recovery and fewer retinal detachments, supporting a definitive phase 3 study.
Wednesday, July 29, 2026
The transaction would bring together IPG's photonics expertise and Lumibird's opthalmic laser portfolio.
Tuesday, July 28, 2026
The pivotal study will evaluate the Preserflo MicroShunt in adult patients with primary open-angle glaucoma who failed previous medical and surgical treatment.
Monday, July 27, 2026
The submission is supported by results from the phase 3 Mont Blanc and Denali clinical trials which demonstrated clinically meaningful reductions in intraocular pressure with a favorable safety profile.
Monday, July 27, 2026
The randomized, sham-controlled i-SIGHT2 trial is designed to evaluate the safety and effectiveness of the noninvasive, office-based bioelectric therapy in patients with vision loss due to dry AMD.
Friday, July 24, 2026
The FDA has approved Lytenava (bevacizumab-vikg; Outlook Therapeutics) for the treatment of neovascular age-related macular degeneration, making it the first FDA-approved ophthalmic formulation of bevacizumab in the United States.
Wednesday, July 22, 2026
The society urges use of existing CPT codes to avoid reimbursement delays and preserve access for patients with refractory glaucoma.
Tuesday, July 21, 2026
In the 0.7 mg cohort, the mean rate of geographic atrophy growth was 54% lower than in the pooled group of control eyes over 6 months.
Tuesday, July 21, 2026
The virtual reality ophthalmic training program supports hands-on training in regions of Africa where access to surgical training resources and mentorship opportunities can be limited.
Monday, July 20, 2026
The therapy improved visual acuity and stereoacuity in patients who have amblyopia, particularly older children who had not benefited from prolonged patching therapy.
Thursday, July 16, 2026
The EyeGility Inserter is now available in the US as part of the enVista Aspire preloaded IOLs.
Thursday, July 16, 2026
Galassia-NAION-301 is a multicenter, double-blind study comparing cenegermin-bkbj against placebo in improving vision loss caused by non-arteritic anterior ischemic neuropathy.
Wednesday, July 15, 2026
Proposed changes to the Physician Fee Schedule include lower conversion factors, E/M payment revisions, and practice expense reforms.
Monday, July 13, 2026
The study did not achieve its primary endpoint of replicating visual function improvements observed in a smaller phase 1/2a study following 28 days of topical administration for glaucoma.
Monday, July 13, 2026
The new platform is designed to reduce the operational burden that stands between physicians and their patients, Bausch + Lomb said.
Friday, July 10, 2026
IRX-101 is an investigational ocular antiseptic with the potential to improve the standard of care by reducing postprocedural pain and corneal toxicity in patients receiving intravitreal therapy, said Tarsus Pharmaceuticals.
Friday, July 10, 2026
Prednisolone acetate ophthalmic suspension, USP, 1%, manufactured by Lupin Limited, has been recalled due to the presence of a foreign substance.
Thursday, July 9, 2026
Parents recognize vision is key to school success, yet many teens aren’t getting eye exams, according to an Alcon survey
Wednesday, July 8, 2026
Accessible through VIZZ.com, the integrated telehealth platform connects patients with an independent network of licensed ECPs who will evaluate patient telehealth eligibility based upon their medical history.
Wednesday, July 8, 2026
A new study from Orbis International found that by combining a free smartphone app focused on quality improvement with an investment of $2,500, 11 hospitals in Ethiopia nearly doubled their cataract surgery success rates.
Tuesday, July 7, 2026
EO2002 is the company’s lead investigational magnetic human corneal endothelial cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction.
Tuesday, July 7, 2026
The companies will create a codeveloped technology that enables surgeons to fine-tune visual outcomes for their cataract patients who choose a PCIOL.
Thursday, July 2, 2026
LambdaVision is harnessing the unique space environment to manufacture artificial retinas to restore vision to people blinded by macular degeneration.
Thursday, July 2, 2026
Byooviz (ranibizumab-nuna) is a biosimilar referencing ranibizumab (Lucentis; Genentech)
Wednesday, July 1, 2026
New survey findings show the impact of dry eye can extend beyond the burden of physical symptoms, affecting how patients view their emotional health and wellbeing.
Tuesday, June 30, 2026
The filing application is based on improvements seen across key efficacy endpoints from the global phase 3 SatraGO-1 and SatraGO-2 studies, including proptosis and diplopia in active TED.
Monday, June 29, 2026
The initiative aims to enhance training, consultation, and research in clinical perimetry by establishing a comprehensive educational program designed by the Casey Visual Field Reading Center.
Monday, June 29, 2026
The 510(k)-cleared system is the industry’s first wireless integrated laser indirect ophthalmoscope system.
Monday, June 29, 2026
The company has now fully enrolled both pivotal wet AMD studies ahead of initial projections. Topline data is expected in 2027.
Monday, June 29, 2026
Regenxbio and AbbVie advance suprachoroidal gene therapy sura-vec into phase 2b/3 testing for nonproliferative diabetic retinopathy.
Monday, June 29, 2026
The Optase line of products now includes Eyetamins Eye Comfort and Eyetamins Vision Support
Monday, June 29, 2026
Lumvoa is a full antagonist of IGF-1R and the first approved treatment for TED with labeling that includes data for both active and chronic TED, according to the company.
Thursday, June 25, 2026
The phase 2 study is evaluating an investigational eyelid-applied therapy for Demodex blepharitis.
Wednesday, June 24, 2026
Prevent Blindness has designated July as Dry Eye Month as part of an effort to raise awareness about dry eye disease, offering a variety of free educational resources eyecare professionals can share with their patients.
Tuesday, June 23, 2026
The NDA is supported by data from the phase 3 DRAGON trial, which met its primary endpoint.
Tuesday, June 23, 2026
Enrollment is expected to complete Q1 2027, with topline results anticipated 1H 2028, the company said.
Tuesday, June 23, 2026
The company said it has been informed that the resubmission is a Class 1 review, with a PDUFA target action date of July 29, 2026.
Tuesday, June 23, 2026
Bayer now holds the full rights pertaining to PER-001 intravitreal implant, a sustained release small molecule endothelin receptor antagonist currently in phase 2 clinical development for the treatment of glaucoma and diabetic retinopathy.
Tuesday, June 23, 2026
The collaboration aims to advance glaucoma care through gamified virtual reality (VR) technology and VR-based visual function testing.
Monday, June 22, 2026
The company said the planned submission will include efficacy and safety data from SOL-1 along with interim safety data from the ongoing SOL-R trial.
Wednesday, June 17, 2026
Prevent Blindness has designated June 28 to July 4 as the sixth annual Fireworks Safety Week, an awareness campaign focused on educating the public about the risk of fireworks-related eye injuries ahead of Independence Day celebrations.
Wednesday, June 17, 2026
Zolymbus (bimatoprost ophthalmic gel) 0.01% is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Tuesday, June 16, 2026
The completion of all follow-up exams across both pivotal studies will allow Epion to advance toward regulatory submission to the FDA.
Tuesday, June 16, 2026
The product is available in 30- and 60-count single-use vials.
Thursday, June 11, 2026
Expanded US availability paired with new patient lifestyle quiz encourages informed decision-making ahead of cataract surgery
Thursday, June 11, 2026
The company seeks to improve availability of the FDA-approved treatment for vernal keratoconjunctivitis.
Tuesday, June 9, 2026
The latest version is designed to deliver speed, workflow flexibility, and diagnostic depth to multimodal retinal imaging, the company said.
Tuesday, June 9, 2026
Agreement with Selagine, Inc. supports the development of an investigational pooled plasma biologic platform intended to move beyond individualized compounded serum tears
Tuesday, June 9, 2026
Orunea will enroll 150 adult patients to evaluate whether Cenegermin-bkbj can achieve complete epithelial healing of the cornea.
Tuesday, June 9, 2026
The study will assess gildeuretinol’s potential to reduce the growth rate of retinal atrophic lesions and to preserve visual acuity.
Monday, June 8, 2026
The draft guidance is intended to help developers of cell and gene therapies make greater use of existing scientific and regulatory knowledge when advancing new products.
Friday, June 5, 2026
Ranibizumab-hkdz, an interchangeable biosimilar to Lucentis, will be available in both vial and prefilled syringe formats.
Thursday, June 4, 2026
Prevent Blindness is recognizing June as Cataract Month to raise awareness of the leading cause of vision loss in the United States.
Wednesday, June 3, 2026
The company has also initiated a phase 2 clinical trial with first patients dosed.
Tuesday, June 2, 2026
Topline data for the 15-month primary endpoint are anticipated in the second half of 2027
Tuesday, June 2, 2026
THN391 is an investigational anti-fibrin monoclonal antibody for diabetic macular edema (DME).
Monday, June 1, 2026
Oculis reported the primary endpoint of mean change in best corrected visual acuity from baseline to week 52 in both phase 3 trials was not met.
Monday, June 1, 2026
AI-driven analysis of retinal images may eventually support earlier risk stratification for dementia and stroke, but current evidence remains insufficient to show that these tools improve clinical decisions and patient outcomes, according to a JAMA Ophthalmology Viewpoint.
Monday, June 1, 2026
Patients with evaporative dry eye may find symptom relief.
Wednesday, May 27, 2026
According to Complement Therapeutics, Opti-GAIN investigators reported no significant safety concerns and advanced the gene therapy study to Cohort 2.
Wednesday, May 27, 2026
MCO-010 is being developed as a one-time, intravitreal, disease-agnostic therapy designed to restore vision in patients with photoreceptor loss, including those with retinitis pigmentosa and Stargardt disease.
Wednesday, May 27, 2026
The FDA concluded that substantial evidence of effectiveness has been established for ONS-5010/Lytenava for the treatment of neovascular age-related macular degeneration.
Tuesday, May 26, 2026
Background music and multimedia exposure were associated with lower patient-reported anxiety in a quasi-experimental ophthalmology clinic study that used existing clinic audiovisual infrastructure at no additional cost.
Friday, May 22, 2026
The artificial tear is designed to deliver fast-acting temporary relief for individuals experiencing dry eye symptoms
Friday, May 22, 2026
New York Eye and Ear Infirmary (NYEE) of Mount Sinai Hospital in Manhattan is the first eye center in the greater New York City area to use BVI’s Leos laser technology in a clinical setting, according to a press release. NYEE ophthalmologist Luis Silva, MD, performed the first Leos endoscopic cyclophotocoagulation (ECP) procedure there on May 6.
Friday, May 22, 2026
The product is available in 30-count and 60-count 0.4 mL single-use vials
Tuesday, May 19, 2026
According to the company, the new formulation combines AREDS2 nutrients with a proprietary B-vitamin complex intended to support macular health across a broader range of patients with AMD.
Monday, May 18, 2026
Their approach uses a light-activated technology derived from the photosynthetic membranes of the spinach plant, which enables the eye to stay continuously hydrated.
Monday, May 18, 2026
Additional supportive reimbursement pathway for surgeons may enhance patient access to the BIM-IOL System upon potential commercialization, according to the company.
Friday, May 15, 2026
The screening marked the launch of the new program, which is delivered through Siloam Vision's proprietary telemedicine platform, iTelegen, with ongoing research at the National Center for Maternal and Child Health neonatal intensive care unit in Ulaanbaatar, Mongolia.
Friday, May 15, 2026
The novel anterior keratoplasty approach achieved sustained epithelialization and pain reduction in patients with nonhealing ocular surface disease.
Wednesday, May 13, 2026
The test is designed to provide longitudinal molecular monitoring of disease using a blood sample, with the aim of complementing imaging-based surveillance in patients with uveal melanoma.
Tuesday, May 12, 2026
The connected system enables remote monitoring of overnight patient adherence.
Monday, May 11, 2026
The 2 organizations will create practical and scalable pathways for integrating functional vision endpoints into global, regulated studies, OptymEdge said.
Monday, May 11, 2026
Presentations at ARVO highlighted 12-month XLRS results and 3-year outcomes in LCA1.
Monday, May 11, 2026
At the 2026 meeting of the Association for Research in Vision and Ophthalmology (ARVO), Opus Genetics presented clinical and preclinical data including updated findings from its investigational gene therapy OPGx-LCA5.
Friday, May 8, 2026
Two-year study results from SightGlass Vision affirm high efficacy with contrast management
Friday, May 8, 2026
The resource offers families a centralized, evidence-based guide to childhood myopia treatments, offering clear guidance to help parents and caregivers navigate the growing range of options for their children.
Thursday, May 7, 2026
The study included children aged 4 to 12 years old, which Hoya says is a first.
Thursday, May 7, 2026
New clinical evidence demonstrates the effectiveness and safety of RevitalVision's perceptual learning software in improving visual function across multiple ophthalmic indications.
Thursday, May 7, 2026
Privosegtor will enter registrational testing following FDA agreement on trial endpoints and analysis.
Wednesday, May 6, 2026
The acquisition of Perfuse Therapeutics includes PER-001, an intraocular implant in phase 2 trials for glaucoma and diabetic retinopathy.
Wednesday, May 6, 2026
Each company has ceased production with the manufacturer in question, and has said that only the lot numbers listed were affected.
Wednesday, May 6, 2026
Key outcome measures included axial length, retinal and choroidal thickness, and OCTA parameters.
Tuesday, May 5, 2026
Through the partnership, Namsa and Lexitas will provide device innovators with a single, accountable partner for the entire development lifecycle.
Tuesday, May 5, 2026
The REVEAL‑2 phase 3 clinical trial met its primary endpoint with a highly statistically significant treatment effect.
Tuesday, May 5, 2026
Key findings from the DME AWARE initiative, sponsored by Oculis, highlight the importance of non-invasive treatment options for early intervention in diabetic macular edema management.
Monday, May 4, 2026
Data from the study revealed gains in BCVA of +9 letters at 36 months among patients with extensive coverage of OpRegen cell therapy to the GA lesion site.
Monday, May 4, 2026
During the Retinal Therapeutics Innovation Summit in Denver, Atsena Therapeutics presented interim 6-month results from Part B of the phase 1/2/3 LIGHTHOUSE Trial evaluating ATSN-201 in patients with X-linked retinoschisis.
Monday, May 4, 2026
The transaction is expected to close in early 2027.
Thursday, April 30, 2026
The initiative provides eyecare professionals with a suite of downloadable materials they can share with their patients, including updated fact sheets, social media graphics, expert and patient video content, and a new podcast episode.
Thursday, April 30, 2026
In the campaign, animated characters engage in everyday eye-related situations to raise awareness and prioritize eye health and safety.
Thursday, April 30, 2026
AI Scribe operates directly inside the RevolutionEHR encounter workflow, capturing provider commentary during exams and automatically populating structured chart fields for review and approval.
Tuesday, April 28, 2026
Eric Rosenberg, DO, MSE, performed the procedure at SightMD's advanced surgical facility in October. This is the first time a cataract surgeon has used a spatial computing headset as the primary visualization interface.
Tuesday, April 28, 2026
Claire unifies data for actionable insights so clinicians can efficiently meet MIPS requirements and maximize program performance, the company said.
Tuesday, April 28, 2026
The summit will explore how AI can be effectively integrated across the full spectrum of disciplines in eye care to enhance innovation, aid in research, improve practice efficiency, and enhance patient care.
Tuesday, April 28, 2026
Prevent Blindness is set to launch its 2026 Focus on Eye Health Webinar Series on May 19, introducing a yearlong program centered on the theme “Powering Partnerships to Advance Eye Health.”
Tuesday, April 28, 2026
The study met the 12-month primary endpoint and met statistical significance and clinical relevance.
Friday, April 24, 2026
Periorbital transcutaneous electrical stimulation may improve blinking and reduce dry eye signs and symptoms
Tuesday, April 21, 2026
The agreement designates Marco Lombart as the exclusive US distributor for the Haag-Streit Lenstar 900 optical biometer and the Octopus 600 and Octopus 900 perimeters.
Tuesday, April 21, 2026
The approval enables advancement of the investigational intraocular magnifier into the next stage of clinical testing.
Tuesday, April 21, 2026
The company's Lacrifresh HydraPF and Lacrifresh HydraMaxPF preservative-free artificial tears are now available at Walmart stores and Walmart.com.
Tuesday, April 21, 2026
Gene therapy for XLRP advances toward filing despite missed primary endpoint.
Tuesday, April 21, 2026
Researchers identified 4 communication challenges in ophthalmic care based on input from patients and ophthalmologists.
Friday, April 17, 2026
Bausch + Lomb’s ONE by ONE Recycling program has collected and recycled a total of 119,715,074 units, or 724,922 pounds, of used contact lenses, eye care, and lens care materials in the United States.
Thursday, April 16, 2026
New J-code for Epioxa, J2789, is set to become effective July 1, 2026
Tuesday, April 14, 2026
Oral presentations at ASCRS featured phentolamine ophthalmic solution 0.75%
Tuesday, April 14, 2026
Data demonstrates stable refractive outcomes through 3 years with dynamic continuous range of vision from far through near.
Friday, April 10, 2026
The primary endpoint is mean change in BCVA from baseline to Year 1 in the study eye, using standardized Early Treatment of Diabetic Retinopathy Study vision.
Friday, April 10, 2026
Tecnis PureSee IOL achieved exceptional distance and intermediate vision, low bothersome visual symptoms, and high tolerance to post-op refractive errors, according to Johnson & Johnson
Friday, April 10, 2026
The updated label allows treatment of retinal vein occlusion-related macular edema beyond 6 months.
Thursday, April 9, 2026
The NEW DAY study assessed the efficacy and safety of Iluvien as baseline therapy in diabetic macular edema.
Thursday, April 9, 2026
The primary endpoint is the percentage of participants who achieve a ≥ 15-letter improvement (3-line gain) from baseline in BCVA at Month 6.
Thursday, April 9, 2026
The Pentacam Cornea OCT combines Scheimpflug technology with a pericentric OCT scanning system.
Wednesday, April 8, 2026
The Bi-Blade+ vitrectomy cutter and Stellaris Elite upgrade target higher flow rates and more stable intraocular pressure under high vacuum.
Tuesday, April 7, 2026
In a phase 3 trial, 77% of patients achieved highly statistically significant proptosis response.
Tuesday, April 7, 2026
Women academic ophthalmologists earned 85 to 91 cents for every dollar earned by men in 2024, with projected compensation parity achievable only at the two lowest ranks and not expected at the professor or department chair level.
Tuesday, April 7, 2026
K.C. Pharmaceuticals, Inc. is voluntarily recalling over 3 million eye drops that were distributed nationwide due to lack of assurance of sterility.
Tuesday, April 7, 2026
The procedure was performed by Dr. Alexey Rapoport, with Dr. Robert Edward T. Ang of the Asian Eye Institute in Manila serving as principal investigator.
Monday, April 6, 2026
According to Alcon, TruPlus is designed to increase depth of focus while maintaining high-quality distance vision.
Friday, April 3, 2026
Cure Blindness Project and The Fred Hollows Foundation announced a strategic partnership aimed at accelerating the elimination of avoidable blindness in Rwanda and Laos by 2035, while addressing cataract backlogs in additional countries.
Friday, April 3, 2026
At the upcoming ASCRS 2026 meeting, Carl Zeiss Meditec AG will highlight a series of digital, AI-driven, and surgical innovations aimed at enhancing cataract and refractive workflows.
Thursday, April 2, 2026
FDA extends dosing intervals for nAMD and DME based on 96-week PULSAR and PHOTON trial results.
Tuesday, March 31, 2026
The clinician-led initiative is designed to generate high-quality clinical and real-world evidence to support advances in interventional glaucoma care.
Tuesday, March 31, 2026
Acquisition will bring 2 differentiated commercialized immunology medicines to Biogen with Empaveli and Syfovre.
Tuesday, March 31, 2026
The system is designed to provide durable canal support without permanent synthetic implants.
Monday, March 30, 2026
REVEAL-1 met the primary endpoint of Q4W proptosis responder rate with a highly statistically significant treatment effect.
Monday, March 30, 2026
According to data referenced in the announcement, a single daily drop of Yuvezzi produces miosis, beginning at approximately 30 minutes postinstillation, that lasts up to 10 hours.
Friday, March 27, 2026
DSP-3077 receives FDA orphan drug designation as the therapy moves into early-phase trials.
Friday, March 27, 2026
The GLOW2 trial showed significant DRSS gains and fewer sight-threatening events with Zenkuda vs sham at one year.
Friday, March 27, 2026
A multicenter study will investigate a prosthetic capsular device for secondary IOL fixation.
Thursday, March 26, 2026
First patient receives a single dose of CTx001 gene therapy for geographic atrophy secondary to AMD.
Thursday, March 26, 2026
The initiative is intended to raise awareness that women face a higher risk of several vision conditions, including age-related macular degeneration, glaucoma, dry eye, and vision changes linked to pregnancy and menopause.
Thursday, March 26, 2026
Crossover study shows greater IOP reduction and reduced medication waste.
Tuesday, March 24, 2026
EYE7 smart glasses integrate an AI assistant to enhance independence for people with vision loss.
Tuesday, March 24, 2026
Twelve-month data from Ocugen’s ArMaDa study support progression toward phase 3.
Monday, March 23, 2026
The new feature allows surgeons to demonstrate the visual effects of monovision during the consultation process.
Monday, March 23, 2026
SYD-101 0.01% significantly reduced myopia progression across all time points tested and met the primary efficacy endpoint at 36 months of confirmed myopia progression of -0.75 D or worse.
Monday, March 23, 2026
At Week 52, the majority of MCO-010-treated patients improved by 2 or more luminance levels in Multi-luminance Shape Discrimination Test.
Monday, March 23, 2026
In a pivotal US trial, the Elios system achieves significant pressure reduction and medication independence.
Friday, March 20, 2026
Prevent Blindness has designated March 23-29 as its first Keratoconus Week, an awareness initiative focused on education and early detection of the eye disease.
Thursday, March 19, 2026
Data showed meaningful improvements in patient-reported quality-of-life outcomes with urcosimod.
Thursday, March 19, 2026
Epioxa provides an incision-free alternative to traditional corneal cross-linking procedures.
Wednesday, March 18, 2026
The data demonstrate visual improvement and potential durability with a single injection.
Tuesday, March 17, 2026
In an effort to support patients through the Epioxa cross-linking treatment journey, Glaukos has introduced EpioxaCareConnect.
Tuesday, March 17, 2026
The companies mutually ended the deal after prolonged regulatory review.
Tuesday, March 17, 2026
Aldeyra said it does not currently expect to pursue additional clinical trials, and intends to expeditiously request a Type A meeting to understand the actions needed for NDA approval.
Friday, March 13, 2026
Nanodropper says the tool may help patients identify barriers to consistent treatment.
Thursday, March 12, 2026
The extended depth of focus lens expands Johnson & Johnson’s cataract surgery portfolio.
Wednesday, March 11, 2026
The new brand reflects the company’s expansion beyond visual field testing to a broader diagnostic platform with integrated clinical workflows.
Wednesday, March 11, 2026
Through a new partnership with Eyoto, DigitalOptometrics is introducing a new fully automated, remote-powered 4K digital slit lamp integrated into a tele-ophthalmic care platform.
Tuesday, March 10, 2026
Data from the phase 1/2 trial demonstrate sustained IOP reduction and preserved visual acuity in open-angle glaucoma and ocular hypertension patients.
Tuesday, March 10, 2026
Data from a phase 2a study in China suggest visual acuity gains and potential treatment durability.
Tuesday, March 10, 2026
The data expansion initiative is focused on enabling research of traditionally difficult to access image modalities.
Tuesday, March 10, 2026
The expansion allows eyecare practices to access EVAA’s AI-powered billing automation and clinical documentation tools without changing their existing EHR system.
Monday, March 9, 2026
New features include intelligent note reconciliation, expanded device compatibility, and streamlined documentation.
Tuesday, March 3, 2026
Harrow said it expects to initiate the study in the first quarter of 2026.
Tuesday, March 3, 2026
During a symposium, investigators presented findings from the phase 3 SOL-1 trial highlighting the intravitreal insert’s durability and improved visual outcomes in patients with nAMD.
Monday, March 2, 2026
The studies, known as COMO and CAPRI, are designed to assess the safety and efficacy of a 6-month dosing regimen compared with on-label aflibercept (Eylea; Regeneron).
Monday, March 2, 2026
Early functional and anatomical gains observed at 3 months in the first adult patient treated with the subretinal gene therapy.
Monday, March 2, 2026
Anikavisc OVD is used intraoperatively to protect the corneal endothelium, maintain anterior chamber depth, and enable controlled surgical manipulation, Rayner said.
Friday, February 27, 2026
VSP Vision Care has released new findings indicating that US employees are spending close to 100 hours per week on screens, with many reporting productivity challenges linked to screen-related visual discomfort.
Friday, February 27, 2026
As part of Workplace Eye Wellness Month in March, Prevent Blindness provides free educational materials that eyecare professionals can share with their patients, designed to help employees and employers protect and maintain eye health.
Thursday, February 26, 2026
If approved, phentolamine ophthalmic solution 0.75% has the potential to offer a pharmacologic treatment option for patients seeking improved visual acuity without reliance on corrective lenses, the company said.
Thursday, February 26, 2026
The articles highlight the use of the Biovance 3L Ocular tri-layer decellularized basement membrane used in ocular surgery and in ocular surface disease applications.
Wednesday, February 25, 2026
A new global review highlights the increasing prevalence of noninfectious ocular redness due to digital eye strain, dry eye disease, allergies, and environmental exposures.
Wednesday, February 25, 2026
Nicox SA presented positive data from the NCX 470 phase 3 studies in 2 podium presentations and a poster at the 2026 American Glaucoma Society Annual Meeting.
Tuesday, February 24, 2026
The trial will evaluate TECLens' quantitative corneal crosslinking technology for noninvasive refractive vision correction.
Tuesday, February 24, 2026
The browser-based software application is designed to enable eyecare professionals to work together more seamlessly by securely sharing data, referring patients, and strengthening their professional networks.
Monday, February 23, 2026
The prestigious award honors individuals who demonstrate exemplary dedication to humanitarian efforts with a focus on addressing cataract blindness and disability.
Thursday, February 19, 2026
Prevent Blindness has declared the third annual Retinopathy of Prematurity (ROP) Awareness Week, Feb. 23 to March 1, as part of its ongoing ROP Education and Support Initiative.
Wednesday, February 18, 2026
Total30 Multifocal for Astigmatism is the only monthly multifocal toric contact lens with Water Gradient Technology, according to Alcon.
Wednesday, February 18, 2026
The expansion extends EVO ICL use for patients 21 to 60 years old.
Tuesday, February 17, 2026
AI retinal scans already performed in the NICU could flag infants at risk for serious lung disease before standard diagnosis
Tuesday, February 17, 2026
The trial met its primary endpoint at week 36, with 74.1% of Axpaxli-treated subjects maintaining visual acuity compared with 55.8% in the aflibercept arm.
Monday, February 16, 2026
A new study finds nearly half of all people facing cataract-related blindness worldwide still need access to surgery.
Friday, February 13, 2026
This is the second generic FDA approval of this complex suspension product.
Thursday, February 12, 2026
The dose-escalating study will evaluate the safety, tolerability, and exposure of STK-002, a potential disease-modifying medicine, in people with autosomal dominant optic atrophy (ADOA).
Wednesday, February 11, 2026
Researchers from the National Institutes of Health use AI to develop a 3D atlas of healthy and diseased RPE cell states.
Wednesday, February 11, 2026
The 8-week virtual course provides participants with foundational knowledge in anatomy, ocular disease, diagnostics, optics, and patient safety.
Wednesday, February 11, 2026
Ametek has announced its acquisition of LKC Technologies.
Wednesday, February 11, 2026
The phase 3 4FRONT-1 study compares 4D-150, an investigational gene therapy, against aflibercept 2 mg in treatment-naïve patients.
Tuesday, February 10, 2026
Initial cases signal the start of a phased US rollout of the presbyopia-correcting IOL platform, BVI reports.
Friday, February 6, 2026
Under the agreement, MeiraGTx will receive exclusive rights to ZipBio's first-in-class therapies for geographic atrophy, targeting the complement pathway.
Tuesday, February 3, 2026
This enhanced integration allows primary care providers, endocrinologists, and diabetes centers to perform on-the-spot diabetic eye exams without physician interpretation
Monday, February 2, 2026
The platform is managed through a user-friendly clinic dashboard, and is customizable to suit clinic branding and workflows.
Thursday, January 29, 2026
Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, previously known as Brimochol PF, is the first dual-agent eye drop for the treatment of presbyopia in adults.
Wednesday, January 28, 2026
Updated labeling permits repeat implantation in patients meeting corneal safety criteria.
Tuesday, January 27, 2026
Prevent Blindness is providing free educational resources on AMD and low vision including patient and expert videos, webpages, fact sheets, and more.
Tuesday, January 27, 2026
In an imaging study from the Bascom Palmer Eye Institute, Qlosi's low-concentration formulation with 0.4% pilocarpine significantly reduced pupil diameter while demonstrating ciliary muscle movement the same as balanced salt solution control.
Monday, January 26, 2026
The clearance allows initiation of the phase 2 EYETAC clinical trial in patients with noninfectious anterior uveitis.
Monday, January 26, 2026
Under the agreement, BioStem will acquire exclusive rights to the Neox and Clarix product lines.
Monday, January 26, 2026
OpCT-001 is an investigational induced pluripotent stem cell–derived cell therapy being tested in a phase 1/2a clinical study for the treatment of primary photoreceptor diseases, including retinitis pigmentosa and cone-rod dystrophy.
Friday, January 23, 2026
A pair of registrational trials will compare the company’s bimatoprost-eluting lens to a standard lens plus drops.
Tuesday, January 20, 2026
The preservative-free eye drops are available in single-dose vials.
Tuesday, January 20, 2026
Sakigake and Orphan Drug designations granted; FDA has conditionally approved the Mogenry brand name.
Tuesday, January 20, 2026
Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs control
Tuesday, January 20, 2026
Dr. Reddy’s olopatadine hydrochloride ophthalmic solution USP, 0.7% is an antihistamine eye drop, indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander, the company said.
Friday, January 16, 2026
TheraTears announced 2 new additions to its portfolio launching nationwide in February 2026: TheraTears Eyelid Cleansing Wipes and TheraTears Dry & Tired Preservative Free Lubricant Eye Drops.
Wednesday, January 14, 2026
The company said that surgeons and clinical teams can benefit from faster setup, quicker patient turnover, and greater mobility.
Tuesday, January 13, 2026
Positive clinical data shows improvement in visual function in patients with infantile nystagmus
Tuesday, January 13, 2026
The strategic partnership expands Topcon's home monitoring and connected-care vision by combining its imaging, AI analytics, and interoperable platforms with RemoniHealth’s remote-monitoring technology.
Tuesday, January 13, 2026
For 3 decades, OM has delivered authoritative coverage of clinical advancements, innovations in surgical technique, regulatory and reimbursement changes, and best practices for efficiency and leadership.
Thursday, January 8, 2026
The next-generation VEGF/Ang2 bispecific antibody demonstrates rapid retinal drying and vision gains in patients with diabetic macular edema.
Thursday, January 8, 2026
Complement Therapeutics’s CTx001, an investigational gene therapy that targets complement pathways in geographic atrophy, will be evaluated in a phase 1/2 trial in 2026.
Tuesday, January 6, 2026
The phase 1/2 CLARITY trial will collect initial data on the safety, tolerability, and efficacy of GEB-101 in corneal dystrophy patients with TGFBI mutation.
Tuesday, January 6, 2026
The designation is supported by results from the phase 2 ACUITY trial, in which Privosegtor was evaluated in patients with acute optic neuritis.
Friday, January 2, 2026
The Digest reflects a global expert consensus on the definitions, risk factors, prevention, and management of myopia in children and young adults.
Friday, January 2, 2026
The FDA indicated that it cannot approve the application in its present form for the treatment of wet age-related macular degeneration.
Friday, January 2, 2026
Ranibizumab-leyk (Nufymco) is approved for all Lucentis indications.
Friday, January 2, 2026
As part of National Glaucoma Awareness Month in January, Prevent Blindness announced the availability of free educational resources on glaucoma that eyecare professionals can share with their patients.
Affiliations:
Specialties:
Areas of Expertise: